DTA’s mission is to broaden the understanding, adoption, and integration of digital therapeutics into mainstream healthcare through education, advocacy, and research.
The Alliance will accomplish this through building networks of diverse stakeholders, mapping the evolving DTx industry landscape, assessing the value and impact of digital therapeutics in clinical practice, generating insights on successful models and outcomes, and encouraging broad collaboration across the healthcare industry.
DTA’s organizational structure ensures the ongoing integrity of our work while enabling expansive member visibility and engagement. The Alliance’s mission and priority initiatives are developed by senior leaders from digital therapeutic companies. DTx member companies must meet key clinical research, product development, quality system, and regulatory engagement qualification criteria.
The Alliance’s Membership Board is composed of representatives from each DTA member organization and oversees progress being made on priority issues. DTA Working Groups, open to participation by all members, are responsible for developing target deliverables.
DTA members include digital therapeutic companies, healthcare providers, payers, academic institutions, patient groups, investors, technology and data organizations, pharmaceutical manufacturers, in addition to other organizations actively engaged in the digital therapeutics industry.
DTA is headquartered in the United States and maintains an international focus on the DTx industry.
The Alliance recognizes the efforts of other healthcare organizations engaged in the evidence-driven advancement of digital therapeutics to improve patient outcomes. DTA is committed to supporting the ongoing work of organizations aligned with the Alliance’s mission.
The Alliance is funded through annual membership dues.
Digital therapeutics are clinically-validated solutions that may be used as standalone direct treatments or in association with other treatments to improve the overall quality, cohesion, outcomes, and value of healthcare delivery. Digital therapeutics demonstrate safety and efficacy in randomized control trials, receive regulatory clearance when used as a medical device, integrate into clinical practice, and are tailored to patients’ clinical needs, goals, and lifestyles. These solutions consist of patient-facing treatments, clinical assessment and outcomes tracking tools, clinician monitoring dashboards, and HIPAA-compliant data storage.